|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Director, Claire Zellerbach Saroni Memorial Tumor Institute of San Francisco, Mount Zion Hospital and Medical Center; Clinical Associate Professor of Radiology, University of California School of Medicine, San Francisco
2 Damon Runyon Fellow at Claire Zellerbach Saroni Memorial Tumor Institute of San Francisco
3 Physicist, Claire Zellerbach Saroni Memorial Tumor Institute of San Francisco; Lecturer in Physics, University of California School of Medicine, San Francisco
1. Transvaginal irradiation is indicated in: patients with cancer of the cervical stump, with hemorrhaging cancer of the cervix, and in patients where intracavitary radium treatment is not possible for cancer of the cervix uteri.
2. Transvaginal cesium 137 therapy is made practical by adapting del Regato applicators to the teletherapy unit, and may be preferable to low kilovoltage radiations because of the better quality of its radiations and improved depth dose immediately beneath the mucosal and tumor surface.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |